PDS BIOTECHNOLOGY ($PDSB) posted quarterly earnings results on Wednesday, August 13th. The company reported earnings of -$0.21 per share, beating estimates of -$0.24 by $0.03. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $PDSB stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
PDS BIOTECHNOLOGY Insider Trading Activity
PDS BIOTECHNOLOGY insiders have traded $PDSB stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PDSB stock by insiders over the last 6 months:
- STEPHEN C. GLOVER purchased 15,061 shares for an estimated $25,001
- GREGORY GENE FREITAG purchased 15,060 shares for an estimated $24,999
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
PDS BIOTECHNOLOGY Hedge Fund Activity
We have seen 19 institutional investors add shares of PDS BIOTECHNOLOGY stock to their portfolio, and 25 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 4,419,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $5,258,610
- VANGUARD GROUP INC added 441,122 shares (+29.2%) to their portfolio in Q2 2025, for an estimated $586,692
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 221,224 shares (-89.6%) from their portfolio in Q1 2025, for an estimated $263,256
- CITADEL ADVISORS LLC removed 220,215 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $262,055
- UBS GROUP AG added 201,098 shares (+401.7%) to their portfolio in Q1 2025, for an estimated $239,306
- RENAISSANCE TECHNOLOGIES LLC removed 100,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $119,000
- MILLENNIUM MANAGEMENT LLC removed 75,791 shares (-60.0%) from their portfolio in Q1 2025, for an estimated $90,191
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PDS BIOTECHNOLOGY Analyst Ratings
Wall Street analysts have issued reports on $PDSB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/01/2025
To track analyst ratings and price targets for PDS BIOTECHNOLOGY, check out Quiver Quantitative's $PDSB forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
